Compare GPRE & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | RGNX |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 761.9M |
| IPO Year | N/A | 2015 |
| Metric | GPRE | RGNX |
|---|---|---|
| Price | $11.69 | $11.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $8.19 | ★ $30.38 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 02-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,246,853,000.00 | $161,318,000.00 |
| Revenue This Year | N/A | $133.58 |
| Revenue Next Year | N/A | $45.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $3.14 | $5.04 |
| 52 Week High | $12.31 | $16.19 |
| Indicator | GPRE | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 57.15 | 36.41 |
| Support Level | $11.40 | $9.51 |
| Resistance Level | $12.27 | $11.78 |
| Average True Range (ATR) | 0.59 | 1.07 |
| MACD | 0.03 | -0.45 |
| Stochastic Oscillator | 61.71 | 25.30 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.